Cytek Biosciences Inc

1. 1

   Election of Class II Directors

   ManagementBoard: FOR

   Elect three Class II director nominees—Vera Imper, Ph.D., Glenn P. Muir and Ming Yan, Ph.D.—each for a three-year term expiring at the 2029 annual meeting.

2. 2

   Non-Binding Advisory Vote to Approve Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   Advisory vote to approve the compensation of the company’s named executive officers for the year ended December 31, 2025 as disclosed in the proxy statement.

   More detail

   This non-binding, advisory "say-on-pay" proposal asks shareholders to approve the compensation paid to Cytek’s named executive officers for 2025 as detailed in the proxy statement. Management seeks shareholder approval to validate its pay-for-performance philosophy and compensation design, which combines base salary, an annual cash incentive tied to revenue and adjusted EBITDA goals, and long-term equity incentives (50% options and 50% RSUs in 2025) targeted to the 50th–75th percentiles of a defined peer group. The Compensation Committee engaged an independent consultant (Meridian) and used a peer group and market data to set salary, target bonus percentages, and equity grant targets; it also adjusted base salaries and target bonuses in 2025 to better align with market medians. The company emphasizes equity-heavy awards to align executive and shareholder interests and uses corporate goals (revenue and adjusted EBITDA) to determine annual cash incentive payouts; the 2025 achievement metrics produced a below-maximum payout (approximately 78.4% for most NEOs). The vote is advisory and non-binding, but the Board states it values shareholder feedback and will consider the vote outcome when setting future compensation policies. The Compensation Committee’s stated rationale for recommending a "FOR" vote is that the program effectively links pay to performance, supports retention and long-term value creation, and reflects remediation and benchmarking efforts after prior stockholder engagement. The proposal is contextualized by recent stockholder outreach around governance and internal control remediation; management notes remediation of previously-identified material weaknesses in internal control over financial reporting as of December 31, 2025. For an institutional investor evaluating this proposal, key considerations include the program’s peer benchmarking, the relative weighting of revenue vs. adjusted EBITDA in bonus calculation, the board’s responsiveness to prior shareholder feedback, and the advisory nature of the vote which allows the Board flexibility while still indicating shareholder sentiment.

3. 3

   Ratification of Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Upcoming shareholder meetings at Cytek Biosciences Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Cytek Biosciences Inc 2026 annual meeting?

Cytek Biosciences Inc (CTKB) holds its 2026 annual shareholder meeting on Wednesday, June 10, 2026.

What is the record date for the Cytek Biosciences Inc 2026 meeting?

The record date for the Cytek Biosciences Inc 2026 meeting is Monday, April 13, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Cytek Biosciences Inc's 2026 meeting?

The board is presenting 3 director nominees at the Cytek Biosciences Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Cytek Biosciences Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Cytek Biosciences Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.